Breaking News
Psilocybin Matches SSRI for Moderate-to-Severe Depression
‘Novel, Striking’ Data on Early CVD Risk Factors and Cognition
Lower COVID-19 rates seen in US states with higher adherence to mask wearing
Here’s How Social Media Affects Your Dopamine Levels
Cuatro respuestas sobre el freno a la vacuna contra covid de Johnson & Johnson
Scientists identify potential drug candidates for deadly pediatric leukemia
Air pollution may affect severity and hospitalization in COVID-19 patients with respiratory disease
Skip to content
  • Health Problems
  • Personal Health
  • Family Health
  • Health News
  • Kids Health
  • Medications
  • Beauty & Balance

FLORESHEALTH

  • Health Problems
  • Personal Health
  • Family Health
  • Health News
  • Kids Health
  • Medications
  • Beauty & Balance

Home ยป (isatuximab-irfc)

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

April 7, 2021Medications

PARIS, March 31, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with…

(isatuximab-irfc), and, approves, Carfilzomib, combination, dexamethasone, FDA, for, in, multiple, myeloma, or, Patients, Refractory, Relapsed, Sarclisa, With
Recent Posts
  • Psilocybin Matches SSRI for Moderate-to-Severe Depression
  • ‘Novel, Striking’ Data on Early CVD Risk Factors and Cognition
  • Lower COVID-19 rates seen in US states with higher adherence to mask wearing
  • Here’s How Social Media Affects Your Dopamine Levels
  • Cuatro respuestas sobre el freno a la vacuna contra covid de Johnson & Johnson
Copyright © All rights reserved.